Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01932060 · ClinicalTrials.gov registry record · Phase 3
Oxytocin Infusions and Blood Loss in Patients Undergoing Elective Cesarean Delivery.
A Phase 3 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 3
- Development phase
- 51
- Enrollment target
NCT01932060: Completed Phase 3 study, sponsored by Stanford University.
NCT01932060 is a Phase 3 study that has completed, run by Stanford University. The registered enrollment target is 51 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01932060, a Phase 3 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 51 participants
- Enrollment target
Study Summary
Although prior dose-finding studies have investigated the optimal bolus dose of oxytocin to initiate adequate uterine tone, it is unclear what oxytocin infusion regimen is required to maintain adequate uterine tone after delivery. The study investigators aim to compare two different infusion rates of oxytocin to assess the optimal infusion regimen for reducing blood loss in women undergoing elective Cesarean delivery.
Interventions
- DRUG Oxytocin Infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2013-08 |
| Est. Completion | 2015-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01932060
The ClinicalTrials.gov registry entry for NCT01932060 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Oxytocin Infusion is the first listed.
NCT01932060 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01932060 about?
NCT01932060 is a clinical study titled "Oxytocin Infusions and Blood Loss in Patients Undergoing Elective Cesarean Delivery.". Although prior dose-finding studies have investigated the optimal bolus dose of oxytocin to initiate adequate uterine tone, it is unclear what oxytocin infusion regimen is required to maintain adequate uterine tone after delivery. The study investigators aim to compare two different infusion rates o...
What is the current status of trial NCT01932060?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 51 participants. The study started on 2013-08. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01932060?
The interventions under investigation include: Oxytocin Infusion (DRUG).
Who is sponsoring clinical trial NCT01932060?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.